Decheng Capital Global Life Sciences Fund IV, L.P.

Decheng Capital Global Life Sciences Fund IV, L.P. discloses dealings in 2 companies, chiefly Aardvark Therapeutics, Inc. and CG Oncology, Inc. Over a trading history stretching from 29 January 2024 to 14 February 2025, the count stands at 7 filings.

Purchases make up the whole of the open-market record (4 purchases, €33.1M). Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. 2025 to date brings 2 purchases and no sales.

The median purchase comes to €8.3M. On 3 out of 3 purchases, another insider of the same company was buying within the same 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

Most recently, on 19 February 2025, the filings show a transaction in Aardvark Therapeutics, Inc. The most recent open-market purchase was published on 19 February 2025, 614 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 5 days. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.